We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pioneering Test Predicts Recurrence and Survival Rates in Breast Cancer Patients

By LabMedica International staff writers
Posted on 02 Oct 2023
Print article
Image: The MAF Test supports informed decisions from pathologists for delivering personalized treatments (Photo courtesy of Inbiomotion)
Image: The MAF Test supports informed decisions from pathologists for delivering personalized treatments (Photo courtesy of Inbiomotion)

Breast cancer is the most frequently diagnosed cancer in women and continues to be the top cause of cancer-related deaths among them globally. Roughly one in eight women will be diagnosed with breast cancer during their lifetime, and out of these, 15-20% will go on to develop metastases. The main culprit behind most fatalities is not the original tumor but its metastatic spread. This makes it crucial to identify patients at a higher risk of recurrence in order to tailor their treatment to improve both their survival chances and quality of life. Now, a new test can provide insights into the prognosis of breast cancer patients. This test aids doctors in identifying those patients who can potentially avoid recurrence and could benefit from supplemental treatment with bisphosphonates, drugs typically used for osteoporosis. The test also flags patients for whom bisphosphonate treatment could be detrimental.

Inbiomotion (Barcelona, Spain) has developed the MAF-TEST after identifying the MAF gene as a key marker for predicting bone metastasis in breast cancer. The diagnostic kit is designed to detect amplification of the MAF gene, allowing for personalized treatment plans for breast cancer patients. The MAF gene plays a vital role, especially in triggering bone metastasis. It regulates a number of cellular processes including cell survival, initiation of metastasis, metabolic changes, and the tumor’s ability to adhere to bone marrow-derived cells. It even influences the formation of osteoclasts, cells that remodel bone. About 20% of breast cancer patients were found to have an amplified MAF gene. Moreover, the presence or absence of this amplified MAF gene significantly alters the response to bisphosphonate treatment in patients with non-metastatic breast cancer, thereby directly affecting their chances of survival.

For oncologists treating breast cancer, the MAF Test offers a groundbreaking addition to their toolkit. It helps identify which patients are more prone to recurrence and could benefit from early alternative treatments. This facilitates a more tailored healthcare strategy, shifting the focus from short-term measures to long-term survival and well-being. It aids in making more informed decisions that could substantially affect the patient's lifespan. Overall, the MAF Test can prove to be an invaluable asset for improving patient outcomes.

"We have described and developed a new test that provides accurate selection criteria for adjuvant bisphosphonate therapy, improving the clinical outcome of breast cancer patients and excluding those who do not benefit,” said Prof. Roger Gomis, co-founder of Inbiomotion. “It is a biomarker that is easy to implement in any clinical pathology laboratory and we believe it should be routine in breast cancer characterization."

Related Links:
Inbiomotion

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.